Thalidomide levels in patients with erythema nodosum leprosum.

Thalidomide is used for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL). In this study, comparisons were made regarding the plasma concentrations of thalidomide in patients with ENL on the course or after leprosy therapy in a prospective clinical trial. Thalidomide concentrations were measured by liquid chromatography on days 1, 3, and 14 of treatment. After 100 mg/d, the thalidomide concentrations ranged from 0.82 to 1.03 and 0.43 to 0.80 microg/mL, on the course or after leprosy therapy, respectively. No differences were observed in thalidomide concentrations between and within the groups. Our results suggested that leprosy multidrug therapy does not seem to affect the plasma concentrations of thalidomide in patients with ENL.
AuthorsJosé Luiz Fernandes Vieira, Maria do Socorro da Silva Valente
JournalTherapeutic drug monitoring (Ther Drug Monit) Vol. 31 Issue 5 Pg. 602-3 (Oct 2009) ISSN: 1536-3694 [Electronic] United States
PMID19704404 (Publication Type: Journal Article)
Chemical References
  • Leprostatic Agents
  • Thalidomide
  • Adult
  • Chromatography, Liquid (methods)
  • Erythema Nodosum (blood, drug therapy)
  • Humans
  • Leprostatic Agents (blood, therapeutic use)
  • Leprosy, Lepromatous (blood, drug therapy)
  • Male
  • Metabolic Clearance Rate
  • Thalidomide (blood, metabolism)
  • Vasculitis (chemically induced, drug therapy)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: